Stock MVR0 MEDIVIR AB
Add to a list
To use this feature you must be a member
Log inSign up

News Medivir AB Deutsche Boerse AG

Equities

MVR0

SE0020181014

Delayed Deutsche Boerse AG
Other stock markets
 08:57:50 17/07/2024 BST 		5-day change 1st Jan Change
0.22 EUR -3.51% Intraday chart for Medivir AB -11.65% +0.55%
06-27 Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma CI
06-20 Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Number of shares and votes in Medivir AB on 28 June 2024
AQ
BioStock: Medivir presents promising results in difficult-to-treat patient population
AQ
Medivir : Presentation
PU
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
AQ
Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma
CI
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024.
CI
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility
AQ
Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility
CI
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024
AQ
Medivir to present at Redeye Growth Day
AQ
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
PU
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program
AQ
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
AQ
Medivir Aktiebolag Approves Board Appointments
CI
BioStock: Double thumbs up for Medivir from the FDA
AQ
Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
AQ
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
AQ
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MVIR B Stock
  4. MVR0 Stock
  5. News Medivir AB